pharma · COVID-19
Hipra Human Health S.L.
Labiana Health drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Labiana Health drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J07) compound in Labiana Health's portfolio. Mechanism: Biological vaccine - induces immune response.
Antiinfectives for systemic use (J07) compound in Labiana Health's portfolio. Molecular target: Spike glycoprotein.
Antiinfectives for systemic use (J07) compound in Labiana Health's portfolio. Mechanism: Biological vaccine - induces immune response.
Development asset linked to Labiana Health in public FDA and regional records.
Development asset linked to Labiana Health in public FDA and regional records.
Development asset linked to Labiana Health in public FDA and regional records.